Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > News > Semi-Annual Changes to the NASDAQ Biotechnology Index

May 10th, 2008

Semi-Annual Changes to the NASDAQ Biotechnology Index

Abstract:
The NASDAQ OMX Group, Inc. ("NASDAQ") (Nasdaq:NDAQ) announced today the results of the semi-annual re-ranking of the NASDAQ Biotechnology Index(r) (Nasdaq:NBI), which will become effective with the market open on Monday, May 19, 2008.

The re-ranking will result in 5 securities being added to the Index. All securities are classified according to the Industry Classification Benchmark (ICB) as either biotechnology or pharmaceutical. The securities that meet the classification criteria then must meet other Index eligibility criteria including listing on the NASDAQ Global Market or the NASDAQ Global Select Market and meeting minimum requirements for market value, average daily share volume and seasoning as a public company. The Index is ranked on a semi-annual basis in May and November. For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visit www.NASDAQ.com.

As a result of the re-ranking, AtheroGenics, Inc. (Nasdaq:AGIX), Anadys Pharmaceuticals, Inc. (Nasdaq:ANDS), CuraGen Corp. (Nasdaq:CRGN), Labopharm, Inc. (Nasdaq:DDSS), NitroMed, Inc. (Nasdaq:NTMD), Panacos Pharmaceuticals, Inc. (Nasdaq:PANC), SciClone Pharmaceuticals, Inc. (Nasdaq:SCLN) and Verenium Corporation (Nasdaq:VRNM), will be removed from the Index.

Added:

AMAG Pharmaceuticals, Inc., (Nasdaq:AMAG) is a biopharmaceutical company. The Company utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease.

Biodel Inc. (Nasdaq:BIOD) is a pharmaceutical company focused on the development and commercialization of treatments for endocrine disorders such as diabetes and osteoporosis.

MiddleBrook Pharmaceuticals, Inc. (Nasdaq:MBRK) develops and commercializes drug products used in the treatment of infectious disease. The Company's drugs attempt to kill bacteria by exposing it to sequential bursts, or pulses of the medication instead of the standard antibiotic treatment regimens.

Pharmasset, Inc. (Nasdaq:VRUS) is a pharmaceutical company. The Company develops oral therapeutics for the human immunodeficiency virus (HIV), hepatitis B (HBV), and hepatitis C (HCV).

Synta Pharmaceuticals Corp. (Nasdaq:SNTA) is a biopharmaceutical company developing small-molecule drugs for inflammatory diseases, cancer, and diabetes. The Company has drug candidates in human clinical trials and additional programs in preclinical studies.

Source:
mondovisione.com

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

GLOBALFOUNDRIES Announces Availability of 45nm RF SOI to Advance 5G Mobile Communications: Optimized RF features deliver high-performance solutions for mmWave beam forming applications in 5G smartphones and base stations February 22nd, 2017

EmTech Asia breaks new barriers with potential applications of space exploration with NASA and MIT February 22nd, 2017

JPK selects compact tensile stage from Deben for their NanoWizard® AFM platform to broaden capabilities for materials characterisation February 22nd, 2017

Molecular phenomenon discovered by advanced NMR facility: Cutting edge technology has shown a molecule self-assembling into different forms when passing between solution state to solid state, and back again - a curious phenomenon in science - says research by the University of Wa February 22nd, 2017

Investments/IPO's/Splits

Harris & Harris Group Announces the Filing of Preliminary Proxy Materials Detailing Its Proposed Conversion From a BDC to a Registered Closed-End Fund January 24th, 2017

Harris & Harris Group Issues Reminder for Shareholder Update Call on January 10, 2017 January 10th, 2017

Arrowhead Provides Response to New Minority Shareholder Announcement January 7th, 2017

Harris & Harris Group Announces a Proposed Strategic Restructuring December 20th, 2016

Nanomedicine

Nominations Invited for $250,000 Kabiller Prize in Nanoscience: Major international prize recognizes a visionary nanotechnology researcher February 20th, 2017

Good vibrations help reveal molecular details: Rice University scientists combine disciplines to pinpoint small structures in unlabeled molecules February 15th, 2017

In-cell molecular sieve from protein crystal February 14th, 2017

Cedars-Sinai, UCLA Scientists Use New ‘Blood Biopsies’ With Experimental Device to Speed Cancer Diagnosis and Predict Disease Spread: Leading-Edge Research Is Part of National Cancer Moonshot Initiative February 13th, 2017

Announcements

GLOBALFOUNDRIES Announces Availability of 45nm RF SOI to Advance 5G Mobile Communications: Optimized RF features deliver high-performance solutions for mmWave beam forming applications in 5G smartphones and base stations February 22nd, 2017

EmTech Asia breaks new barriers with potential applications of space exploration with NASA and MIT February 22nd, 2017

JPK selects compact tensile stage from Deben for their NanoWizard® AFM platform to broaden capabilities for materials characterisation February 22nd, 2017

Molecular phenomenon discovered by advanced NMR facility: Cutting edge technology has shown a molecule self-assembling into different forms when passing between solution state to solid state, and back again - a curious phenomenon in science - says research by the University of Wa February 22nd, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project